Extended indication Patients with Atopic Dermatitis 12 Years and older.
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Risankizumab
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Skin diseases
Extended indication Patients with Atopic Dermatitis 12 Years and older.
Proprietary name Skyrizi
Manufacturer Abbvie
Mechanism of action Interleukin inhibitor
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional comments IL-23 remmer

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date 2022
Expected Registration May 2023
Orphan drug No
Registration phase Clinical trials
Additional comments Fabrikant verwacht registratie in mei 2023.

Therapeutic value

Current treatment options Ciclosporine A, methotrexaat, azathioprine, mycofenolaat mofetil/mycofenolzuur en dupilumab
Therapeutic value No estimate possible yet
References NCT03706040

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 15,000.00
References Horizonscan dupilumab;
Additional comments De prijs voor risankizumab zal waarschijnlijk vergelijkbaar zijn met dupilumab. De prijs van dupilumab voor deze leeftijdsgroep bedraagt per patiënt per jaar: €15.000,70 (uitsluitend in het eerste jaar €576,95 erbij voor een éénmalige oplaaddosis).

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.